Earn points on every order New products in stock Free 51-page beginner’s guide

Lilly vs Novo: The 2027 Obesity Pipeline Scorecard

Strip away the press releases and the two companies are running opposite strategies. Lilly is widening the mechanism — more receptors, more routes, more combinations — and winning on raw efficacy. Novo is deepening one mechanism — amylin — and winning on time to a decision. The scorecard below scores both on the dimensions that actually determine who leads in 2028.

Last verified: November 4, 2026 Dimensions scored: 7 Decisive year: 2027 Not investment advice
Evidence note & disclosures: This is a research comparison of clinical and regulatory position, not a valuation, forecast or investment recommendation. Trial results are the sponsors' primary estimands and are not directly comparable across different populations and durations. All pipeline assets named except approved products remain investigational. Standard Labs supplies research materials for in vitro and laboratory use only.

⚡ Quick Answer: Who Leads the Obesity Pipeline?

Lilly leads on efficacy, breadth and route of administration. Novo leads on time to the next regulatory decision. Lilly has the only approved oral small-molecule GLP-1 for weight management, the highest weight-loss numbers in the category (retatrutide, −25.0% intention-to-treat), and a non-incretin asset in bimagrumab that no competitor has. Novo has the first GLP-1/amylin combination approaching an FDA verdict and a deeper amylin bench, but CagriSema lost its head-to-head with tirzepatide and zenagamtide is a 2030 product. The scorecard is roughly 5–2 Lilly, with Novo holding the nearer catalyst.

Dimension Lilly Novo Edge
Peak efficacy Retatrutide −25.0% ITT CagriSema 20.4% Lilly
Approved oral Orforglipron (small molecule) Oral semaglutide 25 mg (peptide) Lilly
Next decision Retatrutide BLA, Q1 2027 CagriSema FDA, Q4 2026 Novo
Amylin depth Eloralintide, EloraTZP Cagrilintide, zenagamtide Novo

The Scorecard

Dimension Lilly Novo Edge
Approved obesity portfolio Tirzepatide (Zepbound), orforglipron (Foundayo) Semaglutide (Wegovy), oral semaglutide 25 mg, Wegovy 7.2 mg Lilly broader mechanism coverage
Oral strategy Small molecule, no fasting, no cold chain Peptide tablet with absorption enhancer Lilly easier dosing logistics
Peak weight loss −25.0% ITT / −28.3% efficacy (retatrutide 12 mg) 20.4% (CagriSema); 24.3% early (zenagamtide) Lilly on Phase 3 evidence
Amylin program Eloralintide monotherapy and EloraTZP CagriSema, zenagamtide, cagrilintide Novo deepest bench
Next regulatory event BLA filing Q1 2027 FDA decision Q4 2026 Novo by two quarters
Head-to-head record Tirzepatide beat CagriSema in REDEFINE 4 Lost noninferiority vs tirzepatide Lilly
Regulatory risk Unresolved drug-vs-biologic classification Device change and manufacturing questions Even
Non-incretin optionality Bimagrumab (muscle and fat) None in late-stage obesity Lilly
Canadian position Orforglipron filing status unverified CagriSema under review since March 2026 Novo visible file

Where Lilly Leads

1. The efficacy ceiling

Retatrutide's TRIUMPH-1 result — −25.0% by treatment-regimen estimand, −28.3% on the efficacy estimand at 12 mg over 80 weeks — is the highest-quality weight-loss number any company has produced in a Phase 3 obesity trial. Novo's best Phase 3 figure is CagriSema's 20.4%, and its early zenagamtide number (24.3%) came from 125 people over 36 weeks. The TRIUMPH-1 analysis explains why the estimand matters here.

2. Route of administration

Orforglipron is not a peptide. That single fact changes manufacturing cost, cold-chain requirements, and how a patient takes the drug. Novo's oral semaglutide is a peptide formulated with an absorption enhancer — a genuine achievement, but a harder product to make and to take correctly. Lilly's oral advantage is structural, not incremental. The orforglipron breakdown covers the pharmacology.

3. Mechanism breadth

Lilly is running three distinct bets at once: triple agonism (retatrutide), amylin stacking (eloralintide, EloraTZP), and non-incretin biology (bimagrumab). Novo's late-stage obesity portfolio is essentially one bet — amylin on top of GLP-1 — expressed three ways. Breadth is not automatically better, but it diversifies failure. Bimagrumab is the clearest example of an option Novo does not have.

Where Novo Leads

1. Time to a decision

CagriSema's NDA was filed in December 2025 and a decision is guided to Q4 2026. Retatrutide is not filed at all. Novo will almost certainly have an approved amylin combination on the US market before Lilly has an approved triple agonist, and first-to-class still matters commercially even when the data are second-best. See the CagriSema decision tracker.

2. Depth in amylin

Novo has cagrilintide as a standalone asset, CagriSema as a combination, and zenagamtide as a unimolecular fusion of amylin and GLP-1. Lilly has eloralintide and EloraTZP. Novo's bench is deeper, and its cagrilintide programme has the longest safety record in the class.

3. An oral peptide franchise

Oral semaglutide 25 mg is approved and produced −13.6% at 64 weeks. That is a weaker number than any injectable in this comparison, but it defends the franchise at the low end and gives Novo a pill that does not depend on a small-molecule manufacturing base. The OASIS-4 analysis has the details.

The 2027 Swing Factors

  • Q4 2026 CagriSema's label An approval with a clean label and broad indication strengthens Novo's position. A narrow label or a CRL weakens it for years.
  • Q1 2027 Whether the FDA accepts retatrutide's BLA Acceptance starts a review clock and a twelve-year exclusivity argument. A refuse-to-file resets everything. See the filing analysis.
  • 2027 EloraTZP Phase 3 enrollment If the amylin-plus-tirzepatide combination reproduces its 23.3% Phase 2b result, Lilly takes the amylin story away from Novo.
  • 2027–2029 Zenagamtide's AMAZE readouts Novo's unimolecular bet has the highest upside and the longest timeline. AMAZE 1 completes in 2029.

What the Scorecard Does Not Measure

  • Price and access. A 25% weight-loss drug that payers restrict is worth less than a 20% drug on formulary. Neither company's contracting position is visible in trial data.
  • Outcomes trials. Cardiovascular and renal outcome data increasingly determine reimbursement. MACE and HFpEF results are pending across the class.
  • Real-world adherence. Every efficacy number above assumes people stay on treatment. Discontinuation rates in the real world are higher than in trials, and a weekly pen beats a quarterly infusion on that measure.
  • Manufacturing. Peptide supply, device supply and fill-finish capacity have constrained this category repeatedly. Neither pipeline is immune.

What This Means for Research Coverage

For anyone publishing in this space, the scorecard points to three content gaps that are currently under-covered: the regulatory mechanics of the retatrutide filing, the body-composition story that bimagrumab makes unavoidable, and the head-to-head reality that CagriSema's own data contradict most of its coverage. Efficacy explainers are everywhere; the interpretive layer is not.

Related Reading

Explore Our Research Tools

Sources

Scorecard verdict: Lilly wins on the science and Novo wins on the calendar. That is a real advantage for Novo and a temporary one for Lilly — first approval of an amylin combination buys market position that efficacy data alone cannot, but it does not change the fact that CagriSema lost its head-to-head and zenagamtide is years away. The 2027 question is not who has the better molecule; it is whether Lilly's filing survives the FDA's classification objection and whether Novo's first-mover approval converts into durable share.

← View all clinical research, trials & peptide analyses in our Blog Archive

Free resource

New to peptide research?

The free 51-page guide covers 12 compound profiles, reconstitution math, COA reading and storage — without the hype.

Get the free guide →Or start with the 2-page checklist

Or browse every guide in the library.